148 related articles for article (PubMed ID: 21373201)
41. Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.
Collak FK; Yagiz K; Luthringer DJ; Erkaya B; Cinar B
J Biol Chem; 2012 Jul; 287(28):23698-709. PubMed ID: 22619175
[TBL] [Abstract][Full Text] [Related]
42. The protein kinase C super-family member PKN is regulated by mTOR and influences differentiation during prostate cancer progression.
Yang CS; Melhuish TA; Spencer A; Ni L; Hao Y; Jividen K; Harris TE; Snow C; Frierson HF; Wotton D; Paschal BM
Prostate; 2017 Nov; 77(15):1452-1467. PubMed ID: 28875501
[TBL] [Abstract][Full Text] [Related]
43. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics.
Dai B; Kong YY; Ye DW; Ma CG; Zhou X; Yao XD
BJU Int; 2009 Oct; 104(7):1009-16. PubMed ID: 19389013
[TBL] [Abstract][Full Text] [Related]
44. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.
Ma T; Chen H; Wang P; Yang N; Bao J
Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162
[No Abstract] [Full Text] [Related]
45. Insulin-like growth factor I suppresses bone morphogenetic protein signaling in prostate cancer cells by activating mTOR signaling.
Wahdan-Alaswad RS; Song K; Krebs TL; Shola DT; Gomez JA; Matsuyama S; Danielpour D
Cancer Res; 2010 Nov; 70(22):9106-17. PubMed ID: 21062988
[TBL] [Abstract][Full Text] [Related]
46. mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer.
Chen X; Cheng H; Pan T; Liu Y; Su Y; Ren C; Huang D; Zha X; Liang C
Mol Carcinog; 2015 Oct; 54(10):1086-95. PubMed ID: 25043657
[TBL] [Abstract][Full Text] [Related]
47. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
48. A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk.
Cao Q; Ju X; Li P; Meng X; Shao P; Cai H; Wang M; Zhang Z; Qin C; Yin C
PLoS One; 2012; 7(11):e50302. PubMed ID: 23209702
[TBL] [Abstract][Full Text] [Related]
49. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.
Morgan TM; Koreckij TD; Corey E
Curr Cancer Drug Targets; 2009 Mar; 9(2):237-49. PubMed ID: 19275762
[TBL] [Abstract][Full Text] [Related]
50. PKM2 Knockdown Induces Autophagic Cell Death via AKT/mTOR Pathway in Human Prostate Cancer Cells.
Dey P; Kundu A; Sachan R; Park JH; Ahn MY; Yoon K; Lee J; Kim ND; Kim IS; Lee BM; Kim HS
Cell Physiol Biochem; 2019; 52(6):1535-1552. PubMed ID: 31135122
[TBL] [Abstract][Full Text] [Related]
51. Genetic variants in mTOR-pathway-related genes contribute to osteoarthritis susceptibility.
Xu Z; Yang H; Zhou X; Li J; Jiang L; Li D; Wu L; Huang Y; Xu N
Int Immunopharmacol; 2019 Dec; 77():105960. PubMed ID: 31704287
[TBL] [Abstract][Full Text] [Related]
52. Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells.
Bianchini A; Loiarro M; Bielli P; Busà R; Paronetto MP; Loreni F; Geremia R; Sette C
Carcinogenesis; 2008 Dec; 29(12):2279-88. PubMed ID: 18809972
[TBL] [Abstract][Full Text] [Related]
53. Association of MTOR and AKT Gene Polymorphisms with Susceptibility and Survival of Gastric Cancer.
Piao Y; Li Y; Xu Q; Liu JW; Xing CZ; Xie XD; Yuan Y
PLoS One; 2015; 10(8):e0136447. PubMed ID: 26317520
[TBL] [Abstract][Full Text] [Related]
54. Contribution of the L-Type Amino Acid Transporter Family in the Diagnosis and Treatment of Prostate Cancer.
Zhao X; Sakamoto S; Wei J; Pae S; Saito S; Sazuka T; Imamura Y; Anzai N; Ichikawa T
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047148
[TBL] [Abstract][Full Text] [Related]
55. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.
Audet-Walsh É; Dufour CR; Yee T; Zouanat FZ; Yan M; Kalloghlian G; Vernier M; Caron M; Bourque G; Scarlata E; Hamel L; Brimo F; Aprikian AG; Lapointe J; Chevalier S; Giguère V
Genes Dev; 2017 Jun; 31(12):1228-1242. PubMed ID: 28724614
[TBL] [Abstract][Full Text] [Related]
56. Germ-line sequence variants of PTEN do not have an important role in hereditary and non-hereditary prostate cancer susceptibility.
Xie CC; Lu L; Sun J; Zheng SL; Isaacs WB; Gronberg H; Xu J
J Hum Genet; 2011 Jul; 56(7):496-502. PubMed ID: 21633361
[TBL] [Abstract][Full Text] [Related]
57. MiR-1 inhibits prostate cancer PC3 cells proliferation through the Akt/mTOR signaling pathway by binding to c-Met.
Gao S; Zhao Z; Wu R; Wu L; Tian X; Zhang Z
Biomed Pharmacother; 2019 Jan; 109():1406-1410. PubMed ID: 30551391
[TBL] [Abstract][Full Text] [Related]
58. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
59. Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer.
White MA; Lin C; Rajapakshe K; Dong J; Shi Y; Tsouko E; Mukhopadhyay R; Jasso D; Dawood W; Coarfa C; Frigo DE
Mol Cancer Res; 2017 Aug; 15(8):1017-1028. PubMed ID: 28507054
[TBL] [Abstract][Full Text] [Related]
60. Dual contribution of the mTOR pathway and of the metabolism of amino acids in prostate cancer.
Schcolnik-Cabrera A; Juárez-López D
Cell Oncol (Dordr); 2022 Oct; 45(5):831-859. PubMed ID: 36036882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
